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Abstract: There is mounting evidence to suggest that environmental factors play a major 
role  in  the  development  of  neurodegenerative  diseases  like  ALS  (Amyotrophic  Lateral 
Sclerosis). The non-protein amino acid beta-N-methylamino-L-alanine (BMAA) was first 
associated  with  the  high  incidence  of  Amyotrophic  Lateral  Sclerosis/Parkinsonism 
Dementia  Complex  (ALS/PDC)  in  Guam,  and  has  been  implicated  as  a  potential 
environmental factor in ALS, Alzheimer’s disease, and other neurodegenerative diseases. 
BMAA has a number of toxic effects on motor neurons including direct agonist action on 
NMDA and AMPA receptors, induction of oxidative stress, and depletion of glutathione. 
As a non-protein amino acid, there is also the strong possibility that BMAA could cause 
intraneuronal  protein  misfolding,  the  hallmark  of  neurodegeneration.  While  an  animal 
model for BMAA-induced ALS is lacking, there is substantial evidence to support a link 
between this toxin and ALS. The ramifications of discovering an environmental trigger for 
ALS  are enormous.  In this  article, we discuss  the history, ecology, pharmacology and 
clinical ramifications of this ubiquitous, cyanobacteria-derived toxin. 
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Amyotrophic  Lateral  Sclerosis  (ALS)  is  a debilitating and fatal neuromuscular disease with  an 
average annual incidence worldwide of 2 per 100,000. Approximately 8–10% of all cases are familial, 
about half of which are characterized by superoxide dismutase mutation (SOD-1). The other 90–92% 
of ALS cases occur sporadically, with no known familial history. At present there is no known cause 
for sporadic ALS, though a number of environmental compounds have been implicated as potential 
etiological agents. The most documented and relatively well established toxicological risk factor for 
ALS  is  smoking  [1–7].  Other  associations  that  have  been  proposed  are  occupational  exposure  to 
electromagnetic radiation [8,9], contact with pesticides and heavy metals such as lead and mercury 
[10–16],  and  possibly  exposure  to  formaldehyde  [17].  Possible  clusters  of  ALS  have  also  been 
described amongst soccer players sharing the same environmental risks and occupational activities 
including frequent head trauma [18–24], but recent reports have also refuted specific links of head 
trauma  to  ALS  [25–27].  Other  forms  of  physical  activity  have  been  debated  and  despite  many 
incidental reports, specific links with ALS have been refuted [28]. Of the environmental triggers for 
ALS, the cyanobacteria-derived neurotoxin BMAA continues to attract attention because of its ability 
to cause neurodegeneration in vitro and its ubiquitous nature [29,30,31–33], providing support for a 
potential role in the etiology of sporadic ALS [29,34,35].  
2. History of Guam and Initial Theory of BMAA 
When  the  United  States  recaptured  the  Marianas  Islands  in  1944  from  Japan,  they  found  an 
extremely  high  incidence  rate  of  ALS  and  ALS-like  conditions  (ALS/  Parkinsonism  dementia 
complex, ALS/PDC), particularly in Guam, where in 1954 it was estimated to be 50–100×  higher than 
the worldwide rate [36–38]. Recent investigations suggest that the incidence and prevalence rates have 
declined considerably over the last 4 decades to levels of 7 per 100,000 that approach rates described 
in the rest of the world [39]. The disease also appears to have evolved over time to predominantly 
present clinically as parkinsonism and dementia rather than ALS. The chief factor responsible for the 
declining incidence appears to be ethnographic changes, social and ecological, brought about by the 
rapid westernization of Guam [39]. The change suggests that the cause of the disease is not genetic but 
rather environmental [39]. Early researchers suspected that something in cycad seeds, a dietary staple 
used by the Chamorro indigenous people to make flour, might be responsible for ALS/PDC [40]. The 
discovery of a neurotoxic non-protein amino acid, beta-N-methylamino-L-alanine (BMAA) in cycad 
flour suggested that this might be the particular cause of ALS/PDC [34,41]. BMAA in cycad seeds is 
derived from symbiotic cyanobacteria in coralloid roots of Cycas micronesica or possibly also from 
the  cycad  plant  itself  [42,43].  BMAA  is  mainly  concentrated  in  proteins  and  was  consumed  by 
Chamorro through multiple dietary sources, including cycad flour, flying foxes (a type of fruit bat), 
and other animals that fed on cycad seeds [42,44–46].  
3. BMAA in Brain Tissue 
In the last ten years, Cox and colleagues have demonstrated that BMAA in cycad seeds is derived 
from symbiotic cyanobacteria in coralloid roots of Cycas micronesica and that BMAA in cycad flour Toxins 2010, 2                        
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is mainly concentrated in proteins. They were able to demonstrate that consumption of cycad flour, 
flying foxes, and other animals that fed on cycad seeds by the indigenous Chamorro people led to bio-
concentration of protein-bound BMAA up the food chain, leading to the accumulation of BMAA in the 
brains of Chamorro patients with ALS/PDC (mean concentration of BMAA 627 µg/g) [34,42,44–47]. 
BMAA has also been detected in the brains of Canadian patients with Alzheimer’s disease (mean 
concentration of BMAA 107 µg/g) but not in control patients without neurological disease [46]. This 
latter  finding  has  recently  been  confirmed  by  a  second  group  (mean  concentration  of  BMAA  in 
Alzheimer’s brains 214 µg/g) and extended to show that BMAA is accumulated in the brains of US 
ALS patients (mean concentration of BMAA 268 µg/g), but not in those of patients with Huntington’s 
disease,  a  genetic  neurodegenerative  disease  (mean  concentration  of  BMAA  11  µg/g)  or  non-
neurological controls (mean concentration of BMAA 41 µg/g) [35]. Huntington’s disease is purely a 
genetic neurodegenerative disease, so the inability to detect BMAA in these specimens is important as 
it suggests that BMAA does not occur as a byproduct of neurodegeneration. 
4. Molecular Mechanisms of BMAA 
Motor neurons are indisputably the largest and longest cells in the body making them vulnerable to 
any  metabolic  or  external  perturbation.  Even  fast  retrograde  and  anterograde  transport  is  a  slow 
process in these very long axons moving at 100 mm/day. Because of the length of these cells, under 
the best of circumstances, it takes as much as two weeks for the fastest moving particles to go from the 
endplate  to  the  cell  body.  Any  small  perturbation  to  transport  or  cellular  hemostasis  by  an 
environmental  toxin  could  have  catastrophic  effects.  BMAA  binds  directly  to  NMDA  and 
AMPA/kainate  receptors  and  binding  is  enhanced  when  the  BMAA  is  carbamated,  producing  a 
molecule that closely resembles glutamate [48,49]. BMAA has been found to induce selective motor 
neuron (MN) loss in dissociated mixed spinal cord cultures at concentrations of approximately 30 µM 
[49], significantly lower than those previously found to induce widespread neuronal degeneration and 
supporting the hypothesis that BMAA may contribute to the selective MN loss in ALS/PDC [49,50]. 
Lobner et al. have shown that the mechanism of neurotoxicity is actually three-fold; it involves not 
only direct action on the NMDA receptor, but also activation of glutamate receptor 5 (mGluR5) and 
induction  of  oxidative  stress  [51].  More  recently  Liu  et  al.  [52]  found  that  BMAA  inhibits  the 
cystine/glutamate antiporter system Xc
- mediated cystine uptake, which in turn leads to glutathione 
depletion  and  increased  oxidative  stress  [52].  In  cyclical-like  pattern,  BMAA  appears  to  drive 
glutamate release via system Xc
- which induces toxicity through activation of the mGluR5 receptor. 
These  multiple  mechanisms  of  BMAA  toxicity  may  account  for  its  ability  to  induce  complex 
neurodegenerative  diseases.  As  pointed  out  by  Bradley  and  Mash  [34],  although  a  single  toxin 
triggering three different neurodegenerative diseases seems unusual, we know that mutations in the 
progranulin gene can result in ALS, AD, PD and PSP phenotypes in North American patients [53–55]. 
Conceivably,  BMAA  could  be  incorporated  into  proteins  and  subsequently  lead  to  protein 
misfolding. The mechanism of BMAA incorporation into protein is not yet known, but a large fraction 
of BMAA is protein bound (60 to 130 fold greater quantity) compared to what has been recovered 
from the free amino acid pool [46]. It is also known that amino acid analogues can be incorporated into 
proteins and can alter cell function [56]. It is not known if BMAA causes misfolding, but there is 
literature showing the misincorporation of even the regular 20 amino acids,  as with disruption of Toxins 2010, 2                        
 
2840 
translational fidelity through the use of low levels of mischarged transfer RNAs (tRNAs) [57]. This 
misincorporation is associated with protein misfolding in terminally differentiated neurons [57]. The 
incorporation of BMAA into protein serves as a potential reservoir for future release of the toxin into 
cells [46]. 
Although there are many examples where BMAA displays neurotoxicity, no good animal model 
exists as of yet [58]. BMAA has been shown to cause motor neuron damage in vivo in brine shrimp 
(Artemia salina [59]), protozoa (Nassula sorex [59]), fruit flies (Drosophila melanogaster [60]), and 
fish (Danio rerio [59,61]). For a meta-analysis of BMAA neurotoxicity in other vertebrates, including 
primates, see Karamyan and Speth [58]. 
The hypothesis that BMAA may be a cause of ALS has its detractors. Snyder et al. reported being 
unable to detect BMAA in the brains of patients with Alzheimer’s disease and Guam ALS/PDC [62] 
and it has been pointed out that BMAA did not cause neurodegeneration in mice within their model 
system  [62,63].  These  observations  have  been  criticized  as  being  based  on  their  own  new  assay 
methods rather than on the established AQC-derivatization assay and for not hydrolyzing the assayed 
material, thereby failing to release and measure the major portion of BMAA that is protein-bound 
[32,34,58]. Later papers from this same research team were able to find BMAA in the brain tissues of 
mice fed BMAA after they developed more sensitive analytical methods [64]. For whatever reason, the 
mouse model may be a poor model to demonstrate the neurotoxicity of BMAA and species-specific 
and  allometric  considerations  are  essential  in  these  types  of  studies  [58].  Despite  these  negative 
findings, the review by Karamyan and Speth [58] concluded that the neurotoxicity of BMAA was 
supported by almost all in vivo studies and is strongly associated with motor function. 
5. Potential Exposures to and Bioaccumulation of BMAA 
The production of BMAA is not confined to cycad seeds, and cyanobacteria species capable of 
producing BMAA are ubiquitously found throughout the world. In some locations, cyanobacteria are 
directly consumed by people and samples of these cyanobacteria have been shown to harbor BMAA. 
People from the Peruvian highlands collect cyanobacterial colonies of Nostoc commune (with a mean 
BMAA concentration of 10 µg/g) and eat them directly, sell them in markets, and add them to salads, 
soups, meat dishes and picante [65]. Likewise, in China, fa cai soup made with Nostoc flageliforme 
(with variable concentrations of BMAA ranging from not detectable to 0.66 µg/g) is eaten as a soup 
during New Year’s celebrations [66]. Unfortunately, epidemiological and human tissue analyses in 
these areas are lacking and higher incidence rates of ALS and ALS-like diseases are unknown.  
Cyanobacterial blooms can occur in both fresh water and marine water bodies, giving the potential 
for human exposure through direct consumption of water, recreational activities, and contaminated 
foodstuffs.  In  the  United  Kingdom,  BMAA  was  prevalent  in  twelve  water  bodies  used  for  either 
drinking  water,  recreation,  or  both  [67].  BMAA  was  found  within  freeze-dried  cyanobacteria 
collections obtained from these British water bodies as both a free amino acid (ranging from  not 
detected to 276 µg/g) and as a protein associated amino acid (ranging from 6 to 48 µg/g). Likewise, 
BMAA has been indentified in scum material collected from urban waters in the Netherlands where 
cyanobacterial blooms are prevalent [68]. Recreational activities, such as swimming and water-skiing, 
are  a  potential  source  of  exposure  to  BMAA  in  areas  with  cyanobacteria  blooms;  aerosol-borne 
exposure  to  another  cyanobacteria  toxin,  microcystin,  has  already  been  documented  [69,70].  In  a Toxins 2010, 2                        
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recent article, Esterhuizen et al. [71] showed that free BMAA can be released during the collapse of 
cyanobacterial blooms. This process combined with cellular turnover creates a latent source of the 
non-protein amino acid for bioaccumulation and biomagnification in aquatic ecosystems. Rapid uptake 
of significant amounts of BMAA was observed in the macrophyte Ceratophyllum demersum [71]. 
Following accumulation of free BMAA, protein association was observed which suggests potential 
bioaccumulation  by  aquatic  macrophytes  and  offers  a  possibility  of  phytoremediation  for  BMAA 
removal [71]. This also suggests a potential route for human exposure to BMAA if it is shown to apply 
more  broadly  to  plants  intended  for  human  consumption.  There  is  evidence  to  show  that  human 
exposure  to  other  toxins  of  cyanobacterial  origin  occurs  in  this  manner  [72].  Bioaccumulation  of 
BMAA is undoubtedly occurring within other organisms outside of the Guam ecosystem.  
Recently, Brand et al. [73,74] found that BMAA is bio-concentrated in crustaceans, mollusks, and 
certain  fish,  particularly  those  that  feed  on  the  benthos.  This  study  provides  one  plausible 
environmental source of the BMAA identified in the South Florida ALS and Alzheimer’s disease 
patients described by Pablo et al. [35]; however, the very important correlative demographics and 
behaviors of individual patients are lacking at this time. The study by Brand et al. [74] has recently 
been  confirmed  in  a  second  marine  ecosystem  in  the  Baltic  Sea  where  the  same  pattern  of  high 
concentrations of BMAA was observed in bottom dwelling fish species and in filter-feeding mollusks 
[31]. Since massive blooms of cyanobacteria (e.g., Nodularia) are a common occurrence in the Baltic 
Sea because of its brackish waters and many organisms from the Baltic Sea are consumed by the 
surrounding  human  populations,  this  represents  a  concern  for  human  health.  Bioaccumulation  of 
BMAA in marine environments is thus entirely feasible [75], but not demonstrated unequivocally as of 
yet. Caller et al. originally identified 9 ALS patients (now 11 ALS patients) who lived near Lake 
Mascoma in Enfield, NH, an incidence of sporadic ALS that is as much as 25 times the expected 
incidence for New Hampshire [76]. They suggested that the high incidence of ALS in this potential 
cluster might be related to a cyanobacteria toxin exposure from frequent cyanobacterial blooms in the 
lake. Blooms of cyanobacteria are found in many New Hampshire lakes each year and are capable of 
producing any number of toxins including BMAA [76]. Postulated mechanisms of BMAA acquisition 
include consuming contaminated fish, ingestion of lake water or possibly infiltration of lake water 
containing BMAA into artesian wells. Another postulated route of cyanotoxin exposure is inhalation of 
aerosolized toxins through wave action, as can occur with brevetoxins [77–80]. Besides wind and 
environmental factors, recreational activities in water bodies containing cyanobacterial blooms could 
potentially  generate aerosolized cyanotoxins  [70]. On an interesting note,  cyanobacteria are major 
components of desert cryptobiotic soil crusts and BMAA was found in the desert crust of the Arabian 
Peninsula,  where  high  winds  constantly  aerosolize  the  sand.  Military  activities  in  the  Arabian 
Peninsula  also  created  significant  dust  and  more  cases  of  ALS  have  been  recorded  in  military 
personnel serving in this area during Gulf War I (Persian Gulf War) than in military personnel who 
were trained but not deployed [81].  
6. Multiple Exposures to Cyanobacterial Toxins 
Cyanobacteria  are  ubiquitous  and  produce  a  number  of  neurotoxins  besides  BMAA,  including 
saxitoxin and anatoxin-a. Some species also produce the liver toxin microcystin which has been linked 
through careful epidemiological studies to liver disease and hepatocellular carcinoma [82–85]. BMAA Toxins 2010, 2                        
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has been shown to be co-produced with microcystin and other potent cyanobacterial toxins [67,86]. In 
addition, BMAA co-occurs with the neurotoxic isomer 2,4-diaminobutyric acid (2,4-DAB) in cycads 
and  cyanobacteria  [68,81,87,88].  It  is  established  that  not  all  cyanobacterial  taxa  are  capable  of 
producing some of the better characterized hepatic and neurologic toxins like microcystin, anatoxin-a, 
anatoxin-a(s), saxitoxin, and cylindrospermopsin. But, it is unclear at present whether all cyanobacteria 
are capable of producing BMAA under favorable conditions, and whether co-exposure to BMAA and 
other  cyanobacterial  toxins  might  potentiate  the  development  of  neurodegenerative  disease.  It  is 
entirely possible that a synergistic effect could be created by exposure to more than one neurotoxin at a 
time. Lobner et al. demonstrated that in vitro, BMAA at concentrations as low as 10μM potentiate 
neuronal damage caused by other insults [51]. 
7. Nutritional Status of Persons Exposed to BMAA 
Lathyrism or neurolathyrism is  a  neurological  disease  of  humans  and  domestic  animals,  
caused  by  consuming  the legume  Lathyrus  sativus.  The  consumption  of  large  quantities  of  
Lathyrus  sativus (400g/day)  containing  high  concentrations  of  the glutamate analogue  neurotoxin  
β-N-oxalyl-amino-L-alanine (BOAA)  causes  a  spastic  paraparesis  [89].  Lathyrism  occurs  during 
periods  of  malnutrition  and  is  often  triggered  by  physical  exhaustion.  Adverse  environmental 
conditions brought on by drought, flood, pestilence and war have forced populations to rely almost 
exclusively  on  food  resistant  to  these  adverse  conditions  such  as  the  Lathyrus  sativus  legume;  a 
situation that leads to the development of Lathyrism [90]. Supplemental food-aid appears to reduce the 
incidence of neurolathyrism in areas of drought and malnutrition [91]. Jahan and Ahmad discovered 
that  experimental  neurolathyrism  could  be  produced  in  guinea  pigs  and  primates  that  needed  an 
external supply of ascorbic acid by making them subclinically deficient in ascorbic acid and feeding 
them  the  seeds  of  Lathyrus  sativus  or  extracts  thereof  [92].  Autoclaving  the  seeds  of  the  
Lathyrus sativus with lime removed the toxin [92]. As with BOAA, it is postulated that BMAA could 
be  more  harmful  to  malnourished  individuals  [93].  ALS/PDC  was  first  discovered  in  Guam  and 
peaked following World War II at a time when the indigenous Chamorro people were malnutritioned. 
By  the  time  it  was  documented,  dietary  intake  was  probably  back  to  near  normal  but  years  of 
malnutrition may have contributed to the overall peak of disease that occurred later.  
8. Latency Effects of BMAA 
The lag time between BMAA exposure and onset of neurodegeneration is not known, however, 
considerable insight can be found from the analysis of migrants to and from Guam. Twenty-eight 
Chamorro migrants from Guam developed ALS/PDC after periods of absence ranging from 1 to 34 
years [94]. These data suggest that if environmental factors are responsible the latency period for 
disease development may be over three decades. Estimates of crude mortality rates from ALS for these 
migrants are at least three times as high as rates noted for the United States population, yet more than 
four times lower than the ALS crude mortality rates for non-migrant Chamorros living in Guam during 
the twenty years prior to the epidemiological study [94] suggesting that the exposure the migrants were 
subjected to occurred in Guam. When considering cases of progressive neurologicial disease among 
Filipino migrants to Guam, ten Filipino migrants to Guam were reported with ALS 1 to 32 years after Toxins 2010, 2                        
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their arrival; two migrants developed parkinsonism-dementia 13 and 26 years after arrival, and seven 
additional patients developed what was considered more classic PD 5 to 24 years after their migration 
to Guam [95]. Ten children born on Guam of Filipino and Chamorro parents also developed ALS and 
six developed PD [95]. The average annual crude mortality rate for ALS among Filipino migrants was 
estimated to be six times higher than those living in the continental United States but half the rate 
observed  among  Chamorros  living  on  Guam  during  the  same  period  [95].  Combined,  these  data 
suggest that environmental exposure precedes neurological symptoms by possibly decades and that 
some  people  are  more  susceptible  to  disease  than  others  due  to  interactions  between  genes  and 
environmental exposure.  
9. Conclusions 
Cyanobacteria are ubiquitous and many of the species examined so far have been shown to produce 
the  neurotoxic  non-protein  amino  acid  BMAA.  Since  human  exposure  to  BMAA  appears  to  be 
widespread, it has the potential to be a major environmental factor capable of causing ALS and other 
neurodegenerative  diseases  throughout  the  world  [34].  The  literature  is  full  of  convincing  spatial 
clusters of ALS and reports of conjugal ALS [24,76,96–103]. A careful evaluation of these clusters in 
relation to potential environmental sources of ALS would be very important as would evaluation of 
brain  and spinal  cord  tissues  for the presence  of BMAA. Although the link between BMAA  and 
sporadic ALS awaits a primate model of BMAA-induced progressive neurodegeneration for better 
confirmation [58], multi-disciplinary studies by investigators at a variety of institutions indicate that 
BMAA should be more carefully investigated as a trigger for ALS acting through gene-environment 
interactions.  
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